Comparing Two Medications to Safely Lower High Heart Rate in Severe Infection: A Study of Ivabradine and Esmolol

Effect of short-term targeted heart rate control with Ivabradine versus Esmolol in septic shock with refractory tachycardia: A randomised controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/094562

Enrollment

100

Registered

2025-09-11

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B950- Streptococcus, group A, as the cause of diseases classified elsewhere

Interventions

Intervention1: Enteral Ivabradine: Enteral Ivabradine compared with Intravenous Esmolol in patients with septic shock and refractory tachycardia Intervention2: Enteral Ivabradine: Ivabradine is given

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients with septic shock (Vasoactive Inotropic score 10 - 50) and sinus tachycardia with a heart rate of more than 110 bpm, after at least 12 hours of ICU admission and stabilization.

Exclusion criteria

Exclusion criteria: VIS score more than 100 safety concerns with Enteral Ivabradine and negative inotropic effects of Esmolol

Design outcomes

Primary

Measure	Time frame
Mean Vasoactive-Inotropic ScoreTimepoint: recorded every 6 hours, up to 54 hours	—

Secondary

Measure	Time frame
Mean heart rateTimepoint: recorded at baseline and every 6 hours, up to 54 hours;Percentage of time-points in which heart rate is within the target rangeTimepoint: From 6 to 54 hrs	—

Countries

India

Contacts

Public ContactDr.Loveneesh Dagar

Department of Anesthesiology Pain Medicine and Critical care AIIMS New Delhi

ajishaa@gmail.com9810597276

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026